New therapies for castrate-resistant prostate cancer

Author： Williams Stephen B Lay Aaron H Lau Clayton S Josephson David Y Wilson Timothy G Choueiri Toni K Pal Sumanta K

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.13, 2011-09, pp. : 2069-2074

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Castrate-resistant prostate cancer: therapeutic strategies

By Harzstark Andrea L Small Eric J

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 6, 2010-04 ,pp. : 937-945

Informa Healthcare

Access to resources Recommend Favorite

Zibotentan for the treatment of castrate-resistant prostate cancer

By Shepard Dale R Dreicer Robert

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 899-908

Informa Healthcare

Access to resources Recommend Favorite

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

By Schelman William Liu Glenn Wilding George Morris Thomas Phung De Dreicer Robert

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 118-125

Springer Publishing Company

Access to resources Recommend Favorite

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

By Wissing Michel D van Diest Paul J van der Wall Elsken Gelderblom Hans

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 5, 2013-06 ,pp. : 635-661

Informa Healthcare

Access to resources Recommend Favorite

Prescribing of docetaxel for castrate-resistant prostate cancer has increased following publication of the TAX327 study and NICE recommendations

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 602, 2010-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite